Latest Synovial sarcoma Stories
INDIANAPOLIS, May 19, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced data from its Phase II study with cixutumumab in five subtypes of sarcoma, a cancer that develops from connective tissues in the body.
CALGARY, Dec. 11 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc.
CALGARY, Nov. 14 /PRNewswire-FirstCall/ -- Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) announced today that a poster presentation authored by Dr.
SALT LAKE CITY, Nov.
By Chotel, F Unnithan, A; Chandrasekar, C R; Parot, R; Jeys, L; Grimer, R J We have analysed the pattern of symptoms in patients presenting with synovial sarcoma to identify factors which led to long delays in diagnosis.
By Litzky, Leslie A * Context.-Sarcomatous pulmonary neoplasms are a rare and diagnostically challenging group of tumors.
By Dishop, Megan K Kuruvilla, Supriya * Context.-Primary lung neoplasms are rare in children, but they comprise a broad and interesting spectrum of lesions, some of which are familiar from other tissue sites, and some of which are unique to the pediatric lung.
ImClone Systems has announced that a Phase II clinical trial of IMC-A12, the company's fully human, IgG1 anti-insulin-like growth factor-1 receptor monoclonal antibody, in adolescents and adult patients with several types of soft tissue sarcoma has opened for patient enrollment.
ImClone Systems Incorporated (NASDAQ: IMCL), a global leader in the development and commercialization of novel antibodies to treat cancer, today announced that a Phase 2 clinical trial of IMC-A12, ImClone's fully human, IgG1 anti-insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody, in adolescents and adult patients with several types of soft tissue sarcoma has opened for patient enrollment.
- The governor of a province or people.